The Secondary Progressive Multiple Sclerosis (SPMS) drugs in development market research report provides comprehensive information on the therapeutics under development for Secondary Progressive Multiple Sclerosis (SPMS), complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA), and molecule type. GlobalData’s report assesses key aspects of the companies and drugs in development for Secondary Progressive Multiple Sclerosis (SPMS). Buy the report here.
Smarter leaders trust GlobalData
The report also covers the descriptive pharmacological action of the therapeutics and the latest news and press releases. Additionally, the report provides an overview of the key players involved in therapeutic development for Secondary Progressive Multiple Sclerosis (SPMS) and features dormant and discontinued products.
GlobalData tracks 36 drugs in development for Secondary Progressive Multiple Sclerosis (SPMS) by 32 companies/universities/institutes. The top development phase for Secondary Progressive Multiple Sclerosis (SPMS) is phase ii with 16 drugs in that stage. The Secondary Progressive Multiple Sclerosis (SPMS) pipeline has 35 drugs in development by companies and one by universities/ institutes. Some of the companies in the Secondary Progressive Multiple Sclerosis (SPMS) pipeline products market are: Sanofi, Novartis and NeuroGenesis.
The key targets in the Secondary Progressive Multiple Sclerosis (SPMS) pipeline products market include CD40 Ligand, B Lymphocyte Antigen CD20, and B Lymphocyte Antigen CD19.
The key mechanisms of action in the Secondary Progressive Multiple Sclerosis (SPMS) pipeline product include B Lymphocyte Antigen CD20 Inhibitor with two drugs in Phase III. The Secondary Progressive Multiple Sclerosis (SPMS) pipeline products include nine routes of administration with the top ROA being Oral and seven key molecule types in the Secondary Progressive Multiple Sclerosis (SPMS) pipeline products market including Small Molecule, and Monoclonal Antibody.
Secondary Progressive Multiple Sclerosis (SPMS) overview
Secondary progressive multiple sclerosis (SPMS) is a form of MS that follows relapsing-remitting MS (RRMS). In RRMS, people experience periods of relapses, when symptoms get worse, and remissions, when symptoms get better. In SPMS, symptoms gradually worsen over time without any clear relapses or remissions. SPMS usually occurs 10 to 15 years after the first MS symptoms, but it can be delayed or prevented by effective disease-modifying therapies (DMTs). SPMS can be active or not active, and with progression or without progression, depending on the presence of relapses, new MRI activity, or increased disability. SPMS is diagnosed by a neurologist based on the clinical history, neurological exam, and MRI scans. MRI scans can show the level of cell death and brain atrophy in MS. Treatment for SPMS may include DMTs to reduce the risk of relapses and slow down the progression of disability, as well as symptom management and rehabilitation strategies to improve quality of life.
For a complete picture of Secondary Progressive Multiple Sclerosis (SPMS)’s pipeline drug market, buy the report here.
Data Insights
From
The gold standard of business intelligence.
Blending expert knowledge with cutting-edge technology, GlobalData’s unrivalled proprietary data will enable you to decode what’s happening in your market. You can make better informed decisions and gain a future-proof advantage over your competitors.
GlobalData, the leading provider of industry intelligence, provided the underlying data, research, and analysis used to produce this article.
GlobalData’s pipeline drugs offers detailed profiles of pharmaceutical drugs in all stages of pre-clinical and clinical development, from discovery through to pre-registration. Coverage is limited to novel human medicinal drugs and biosimilars seeking market approval proprietary and is one of two primary repositories of pharmaceutical drug information offered by GlobalData through its Pharmaceutical Intelligence Center.
